Astonea Labs Ltd
Complete IPO details, including price band, financials, subscription status, and key insights.
Participate in the Astonea Labs Ltd IPO with full transparency. Review issue details, company fundamentals, and financial performance, and apply securely through Alice Blue.
IPO Snapshot
Key metrics and details at a glance.
Price Band
₹135
Per ShareLot Size
1000 Shares
Minimum Investment
₹1,35,000
Issue Size
₹37.67 Cr
Face Value
₹10
Per ShareIPO Type
Book Building - SME
Retail Quota
35%
QIB Quota
50%
NII Quota
15%
IPO Timeline
Important dates for your applying strategy.
Subscription Status
Live demand across investor categories.
Track real-time subscription levels:
*Real-time data subject to exchange updates
Astonea Labs Ltd
Business model, operations, and market positioning.
Promoter Holding (Pre-Issue)
98.42%
Promoter Holding (Post-Issue)
72.3%
Issue Type
Book Building - SME
ISIN
INE0TG901011
About the Company
Our Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products. These include antibiotic drugs, anticold medications, antihistamines, and drugs for diabetes, cardiovascular diseases, gynaecological concerns, analgesics, fungal infections, and multivitamins. We also offer products for skin, tooth, and hair care, available in various forms such as gels, ointments, creams, lotions, oils, and serums. All our products adhere to the rigorous standards of the pharmaceutical and cosmetics industries. Additionally, we are involved in the trading of certain packing materials and raw materials used in pharmaceutical and cosmetic products.
Industry Overview
India is the largest provider of generic drugs globally and is known for its affordable vaccines and generic medications. The Indian Pharmaceutical industry is currently ranked third in pharmaceutical production by volume after evolving over time into a thriving industry growing at a CAGR of 9.43% since the past nine years. Generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research & manufacturing, biosimilars, and biologics are some of the major segments of the Indian pharma industry. India has highest number of pharmaceutical manufacturing facilities that comply with the US Food and Drug Administration (USFDA) and has 500 API producers that make for around 8% of the worldwide API market . The Indian cosmetics sector is currently going through a phase of tremendous expansion. The market for cosmetics in India was estimated to be worth US$ 11.6 billion in 2017 and is projected to expand at a CAGR of 15-20% from 2017 to 2025. The Indian cosmetics sector is expanding for a variety of reasons. The rise of the cosmetic sector has been fuelled by rising purchasing power, rising image consciousness among Indians, and the embrace of Western culture and lifestyle. Since ancient times, India has had an extensive record and a rich tradition of cosmetics. It is currently a thriving sector, and in the upcoming years, it is anticipated to surpass all other countries in terms of cosmetic consumption.
Company History
Our Company was originally incorporated as "AHU Laboratories Private Limited", as a private limited company, under the provisions of the Companies Act, 2013 pursuant to certificate of incorporation dated April 11, 2017. Our Company changed its name from "AHU Laboratories Private Limited" to "Astonea Labs Private Limited" pursuant to Rule 29 of the Companies (Incorporation) Rules, 2014 vide certificate of incorporation dated February 26, 2019. Subsequently, our Company converted into "Astonea Labs Limited", a public limited company vide fresh certificate of incorporation dated January 11, 2024 the Corporate Identification Number of our Company is U24304CH2017PLC041482.
Products & Services
- The Company specializes in the manufacturing and marketing of a wide range of pharmaceutical and cosmetic products.
Growth Strategy
- Expand our scope by adding more products.
- Broaden and deepen presence in existing product portfolio.
- Develop and grow our export division.
- Increase by targeting unexplored markets.
- Leveraging our marketing skills and relationships.
Customer Base
wholesaler and retailer
Financial Performance
Revenue, profit after tax and total assets across the last 2 reported financial years.
Revenue
Amount in ₹ crore
Profit After Tax (PAT)
Amount in ₹ crore
Total Assets
Amount in ₹ crore
Figures in ₹ crore, on a consolidated basis, as reported for FY25 to FY26.
Objects of the Issue
How the company plans to utilize IPO proceeds.
Use of Proceeds
The funds raised through this IPO will be used for:
Public issue of upto 27,90,000 equity shares of face value of Rs. 10/- each ("Equity Shares") of Astonea Labs Limited ("Astonea" or the "Company" or the "Issuer") for cash at a price of Rs. 135/- per equity share including a share premium of Rs. 125/- per equity share (the "Issue Price") aggregating to Rs. 37.67 crores ("the Issue"), of which 1,44,000 equity shares of face value of Rs. 10/- each for cash at a price of Rs. 135/- per equity share including a share premium of Rs. 125/- per equity share aggregating to Rs. 1.94 crores will be reserved for subscription by market maker to the issue (the "Market Maker Reservation Portion"). The issue less the market maker reservation portion i.e. net issue of 26,46,000 equity shares of face value of Rs. 10/- each at a price of Rs. 135/- per equity share including a share premium of Rs. 125/- per equity share aggregating to Rs. 35.72 crores is herein after referred to as the "Net Issue". The issue and the net issue will constitute 26.54 % and 25.17% respectively of the post issue paid up equity share capital of the company.
*Subject to approvals and market conditions.
Strengths & Risks
Key competitive advantages and factors to consider before investing.
- Our experienced management and dedicated employee base.
- Scalable business model.
- Wide and diverse range of product offerings.
- Quality Service.
- The Company has not satisfied the annual OMFUA, under which the FDA assesses and collects fees from qualifying manufacturers of OTC monograph drugs which is mandatory to be paid by all the manufacturers of OTC drugs.
- There have been some instances of delayed and non-filings in the past with the Registrar of Companies which may attract penalties.
- The company is dependent on third parties for the supply of raw materials and such third parties could fails in meeting their obligations, which may have a material adverse effect on its business, results of operations and financial condition. Further its 35.47%, 41.96%, 55.74% and 33.90% of its total purchases are derived from its top 10 suppliers for Financial Years ended on March 31, 2024, March 31, 2023, March 31, 2022 and for the period ended December 31, 2024 respectively.
- The Company, its Promoters, Directors, and Group Companies are party to certain legal proceedings. Any adverse outcome in such proceedings may have an adverse impact on its reputation, business, financial condition, results of operations, and cash flows.
- Its business is significantly dependent on the revenue generated by manufacturing and selling the pharmaceuticals, which constitutes a substantial portion of its sales and such dependence exposes it to various risks that could materially affect its business operations, financial condition, and results of operations.